CardioBrief: Eliquis Nipping At Heels of Top-Selling NOAC Xarelto

(MedPage Today) — Overall market for the new oral anticoagulants continues to expand

Filed under: Cardiovascular

Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials

A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease.

Filed under: COPD

Roche creates the Fight IPF choir for disease awareness campaign

Aims to raise the lung disease’s profile and
inform patients and their families

Filed under: Marketing

Elsevier’s R&D Solutions Welcomes Four Biotech Start-Ups to the Hive

NEW YORK, October 20, 2016 /PRNewswire/ — Incubator Participants Receive Complimentary Access to Elsevier’s Information Solutions to Accelerate Research in Early Drug Discovery and Development Elsevier, a world-leading provider of scientific, technical and medical…

Filed under: R&D

Roche in “unprecedented” launch period for new medicines

Cotellic, Alecensa, Venclexta and Tecentriq position firm to meet 2016 sales targets

Filed under: Company

Pfizer anchoring inflammation hopes in Xeljanz

After a slow launch, the RA drug is picking up speed, leading the big pharma to invest in growing it further.

Filed under: Arthritis

The Power of the Cloud for Life Science R&D

“In the new world, it is not the big fish which eats the small fish, it’s the fast fish which eats the slow fish…” — Klaus Schwab, Founder/Executive Chairman, World Economic Forum Over the past decade, the nature of innovation has changed—even as the pace has substantially increased. One of the reasons has been the ability […]

Filed under: R&D

Roche’s immunotherapy cancer drug given FDA approval

Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given FDA approval for treatment of metastatic non-small cell lung cancer. The figures released earlier this month showed that those taking the drug lived a median of 13.8 months, which worked out, on average, as 4.2 months longer than those being treated with chemotherapy.
read more

Filed under: Cancer, Immunotherapy

Pfizer plans to launch REMICADE biosimilar in US in November

Pfizer said it will begin shipping INFLECTRA (infliximab-dyyb)for injection, a biosimilar of REMICADE (infliximab) to wholesalers in the US in late November 2016.

Filed under: Biosimilar

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk

RIDGEFIELD, Conn., Oct. 17, 2016 /PRNewswire/ — Boehringer Ingelheim today announced new data analyses from the Phase III TONADO® 1&2 trials that build upon existing evidence about the factors that increase the risk of a COPD exacerbation. These data were presented today at the…

Filed under: COPD

Gene Therapy Shows Early Signs of Preventing Alzheimer’s Disease

ArticleThe findings suggest that this therapy would be most effective in the early stages of disease.Staff Author: Ryan BusheyTopics: Biotech

Filed under: Alzheimer’s

Eisai, Arena release BELVIQ XR weight-loss drug

Filed under: Metabolic

NICE backs Celgene’s Otezla for psoriatic arthritis

Celgene’s Otezla is being backed for routine use on the National Health Service in England and Wales to treat psoriatic arthritis.

Filed under: Arthritis

Merck: Promising Results From Immunotherapy Based on Keytruda

Filed under: Cancer, Immunotherapy

Teva, Celltrion Announce Exclusive Biosimilar Commercial Partnership

NewsBoth CT-P10 and CT-P6 are currently in late-stage Phase III development and their primary endpoints have been successfully achieved.Topics: Life Sciences

Filed under: Biosimilar

Pfizer continues trend of shedding non-core assets

Pfizer gets rid of more of the Hospira assets and gains a stake in pure-play infusion therapy company.

Filed under: Company

NICE backs use of Forxiga in triple therapy for diabetes

The National Institute for Health and Care Excellence has now published final draft guidelines endorsing NHS use of AstraZeneca’s Forxiga for treating type II diabetes as part of a ‘triple therapy’.

Filed under: Diabetes, SGLT-2

Novartis shakes up R&D, closing down two biologics units

While two biologics teams will be wound down, elsewhere the Swiss pharma giant plans to open two new research centers and create a unified discovery group.

Filed under: Company

Expert Discusses 2-Year Nivolumab Data and Other Immunotherapy Developments in NSCLC

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non–small cell lung cancer.

Filed under: Cancer, Immunotherapy

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Filed under: Biosimilar